ÂÜÀòÂÒÂ×

Thomas Malley serves as President of Mossrock Capital LLC since May 2007, focusing on investments in public healthcare stocks and venture capital. Malley has held various board positions, including roles at Kura Oncology, Kiniksa Pharmaceuticals, Osmosis Beauty, BeiGene, Ovascience, Puma Biotechnology, and Synageva BioPharma Corp., the latter of which was acquired by Alexion for $8 billion in 2015. Additionally, Malley was Chairman of the Board of Directors for Project C.U.R.E. and served on the Board of Directors for the St. Anthony Health Foundation until May 2015. Malley earned a degree in Biology from Stanford University between 1986 and 1991.